SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from Emergent BioSolutions Inc. (EBS) (CIK 0001367644) (EBS) — Dec 17, 2018

Emergent BioSolutions Inc. (EBS) (CIK 0001367644)
Date: Dec. 17, 2018 · CIK: 0001367644 · Accession: 0001140361-18-045271

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 001-33137

Referenced dates: December 12, 2018

Date
December 17, 2018
Author
By: /S/ RICHARD S. LINDAHL
Form
CORRESP
Company
Emergent BioSolutions Inc. (EBS) (CIK 0001367644)

Letter

RE:

December 17, 2018

VIA EDGAR SUBMISSION

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, NE

Washington, DC 20549

Attention: Christine Torney, Staff Accountant

Emergent BioSolutions Inc.

Form 10-K for the Fiscal Year Ended December 31, 2017

Filed February 23, 2018

Form 10-Q for the Quarterly Period Ended September 30, 2018

Filed November 2, 2018

Form 8-K filed November 1, 2018

File No. 001-33137

Ms. Torney:

Emergent BioSolutions Inc. (the “Company”) is sending this letter to confirm the extension of time within which it will respond to the Staff’s comment letter dated December 12, 2018, relating to the Company's Annual Report on Form 10-K for the year ended December 31, 2017, Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 and Form 8-K, filed November 1, 2018. As agreed, the Company will file its written response to the Staff's comment letter by no later than Friday, January 11, 2019.

If you have any questions, or require any additional information, please contact Brian Millard, Vice President, Corporate Controller, Finance and Administration at (240) 631-3220. Thank you for your assistance.

Regards,
By: /S/ RICHARD S. LINDAHL

Show Raw Text
CORRESP
1
filename1.htm

                December 17, 2018

                  VIA EDGAR SUBMISSION

                  Securities and Exchange Commission

                  Division of Corporation Finance

                  100 F Street, NE

                  Washington, DC 20549

          Attention: Christine Torney, Staff Accountant

                RE:

                Emergent BioSolutions Inc.

                Form 10-K for the Fiscal Year Ended December 31, 2017

                Filed February 23, 2018

                Form 10-Q for the Quarterly Period Ended September 30, 2018

                Filed November 2, 2018

                Form 8-K filed November 1, 2018

                File No.
                      001-33137

              Ms. Torney:

          Emergent BioSolutions Inc. (the “Company”) is sending this letter to confirm the extension of time within which it will respond to the Staff’s comment
              letter dated December 12, 2018, relating to the Company's Annual Report on Form 10-K for the year ended December 31, 2017, Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 and Form 8-K, filed November 1, 2018.  As
              agreed, the Company will file its written response to the Staff's comment letter by no later than Friday, January 11, 2019.

          If you have any questions, or require any additional information, please contact Brian Millard, Vice President, Corporate Controller, Finance and
              Administration at (240) 631-3220.  Thank you for your assistance.

          Regards,

          By: /S/ RICHARD S. LINDAHL

              Richard S. Lindahl

              Executive Vice President,

              Chief Financial Officer and Treasurer

          CC: Jim B. Rosenberg, Senior Assistant Chief Accountant